452339-72-9

Basic information

• Product Name: CarbaMic acid, [(2R)-2-(2,2-diMethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]-, 1,1-diMethylethyl ester
• Synonyms: CarbaMic acid, [(2R)-2-(2,2-diMethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]-, 1,1-diMethylethyl ester;tert-butyl (2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethylcarbamate;(R)-tert-butyl (2-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)-2-hydroxyethyl)carbamate
• CAS NO: 452339-72-9
• Molecular Formula: C₁₇H₂₅NO₅
• Molecular Weight: 323.3841
• Product Categories: Intermediate
• Mol File: 452339-72-9.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 488.6±45.0 °C(Predicted)
• Appearance: /
• Density: 1.143±0.06 g/cm3(Predicted)
• PKA: 12.17±0.46(Predicted)
• CAS DataBase Reference: CarbaMic acid, [(2R)-2-(2,2-diMethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]-, 1,1-diMethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: CarbaMic acid, [(2R)-2-(2,2-diMethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]-, 1,1-diMethylethyl ester(452339-72-9)
• EPA Substance Registry System: CarbaMic acid, [(2R)-2-(2,2-diMethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]-, 1,1-diMethylethyl ester(452339-72-9)

Safety Data

• Hazardous Substances Data: 452339-72-9(Hazardous Substances Data)

Usage

General Description

CarbaMic acid, [(2R)-2-(2,2-diMethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]-, 1,1-diMethylethyl ester is a specific chemical compound that falls under the category of carboxylic acid esters. It is also known by its chemical formula C17H26O5 and has a molecular weight of 310.38 g/mol. CarbaMic acid, [(2R)-2-(2,2-diMethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]-, 1,1-diMethylethyl ester is commonly used in the pharmaceutical and chemical industries for various applications, including as a building block in the synthesis of organic compounds and as an intermediate in the production of active pharmaceutical ingredients. Its unique structure and properties make it a valuable and versatile chemical in the field of organic synthesis.

Upstream product

• 1761-61-1 5-bromosalicyclaldehyde 
• 2316-64-5 5-bromo-2-hydroxybenzyl alcohol 
• 52113-69-6 6-bromo-2,2-dimethyl-4H-benzo[1,3]dioxine 
• 54030-34-1 1-(2,2-dimethyl-4H-benzo[d][1,3]dioxan-6-yl)ethanone 
• 452339-70-7 di-(tert-butyl) 2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxoethyliminodicarbonate 
• 51779-32-9 iminodicarboxylic acid di-tert-butyl ester 
• 452339-71-8 tert-butyl 2-(2,2-dimethyl-4H-1,3-benzodioxane-6-yl)-2-carbonylethylcarbamate 
• 102293-80-1 2-bromo-1-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)ethanone 

Downstream Products

• 452339-73-0 (5R)-5-(2,2-dimethyl- 4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one 
• 503068-36-8 (5R)-3-{6-[(2-{[(2,6-dichlorophenyl)methyl]oxy}ethyl)oxy]-hexyl}-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one 
• 503068-37-9 (2R)-hydroxy-2-(2,2-dimethyl-4Η-1,3-benzodioxole-6-yl)-N-3-[6-[2-[(2,6-dichlorophenyl)methoxy]ethoxy]hexyl]-ethylamine 
• 503068-34-6 4-[(1R)-2-({6-[(2-{[(2,6-dichlorophenyl)methyl]oxy}ethyl)oxy]-hexyl}-amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol 
• 590410-68-7 (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-3-[6-(4-phenylbutoxy)hexyl]-1,3-oxazolidin-2-one 
• 590410-69-8 (R)-1-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)-2-(6-(4-phenylbutoxy)hexylamino)ethanol 
• 135271-47-5 (R)-(-)-salmeterol 

Relevant articles and documents

Method for synthesizing (R)-salmeterol chiral intermediate

The invention discloses a method for synthesizing an (R)-salmeterol chiral intermediate. The method comprises the following steps: adding raw ketone into a solvent C under inert gas shielding, addingalkali to stir for 1-5 hours after dissolving, adding a catalyst A, continuously stirring for 2-4 hours, replacing the inert gas with hydrogen, pressurizing to 30-60atm, stirring under the pressure until the pressure is maintained invariable, thereby obtaining the product (R)-salmeterol chiral intermediate 1. According to the synthetic route in the invention, the (R)-salmeterol chiral intermediatewith high chiral purity can be obtained by virtue of a one-step catalytic hydrogenation reaction, the complicated chiral resolution process in the previous process is saved, the production cost is reduced, the reaction conditions are mild, the process is stable, and the feed stock conversion is greatly improved.

PROCESS FOR THE PREPARATION OF VILANTEROL AND INTERMEDIATES THEREOF

An improved process for the preparation of vilanterol and pharmaceutically acceptable salts thereof is disclosed. More specifically the improved process for preparing intermediates for the preparation of vilanterol is disclosed.

PHENETHANOLAMINE DERIVATIVE FOR THE TREATMENT OF RESPIRATORY DISEASES

The present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.